Clinical trial
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had…
NCT00428714 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00428714 |
|---|---|
| Title | Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy |
| Official title | Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin |
| Enrollment | 73 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jan 1, 2011 |
| First posted | Jan 30, 2007 |
| Last update posted | Nov 25, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: